Case Type: Mergers & Acquisitions

Adamis Pharmaceuticals Corp. (NASDAQ: ADMP), relating to its proposed merger with DMK Pharmaceuticals Corp.

Jounce Therapeutics, Inc. (NASDAQ: JNCE), relating to its proposed merger with Redx Pharma.

Broadmark Realty Capital Inc. (NYSE: BRMK), relating to its proposed merger with Ready Capital Corp. Under the terms of the agreement, BRMK shareholders are expected to receive 0.47233 shares of Ready Capital stock per share they own.

Focus Financial Partners Inc. (NASDAQ: FOCS), relating to its proposed sale to affiliates of Clayton Dubilier & Rice LLC. Under the terms of the agreement, FOCS shareholders are expected to receive $53.00 in cash per share they own.

Vascular Biogenics Ltd. (NASDAQ: VBLT), relating to its proposed merger with Notable Labs, Inc. Under the terms of the agreement, VBLT shareholders are expected to own approximately 24% of the combined company.

Horizon Technology Finance Management LLC (NASDAQ: HRZN), relating to its proposed sale to an affiliate of Monroe Capital LLC.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), relating to its proposed merger with MEI Pharma, Inc.. Under the terms of the agreement, INFI shareholders are expected to own approximately 42% of the newly combined company.

TravelCenters of America Inc. (NASDAQ: TA), relating to its proposed sale to BP plc. Under the terms of the agreement, TA shareholders are expected to receive $86.00 in cash per share they own.

INDUS Realty Trust, Inc. (NASDAQ: INDT), relating to its proposed sale to affiliates of Centerbridge Partners, L.P. and GIC Real Estate, Inc.. Under the terms of the agreement, INDT shareholders are expected to receive $67.00 in cash per share they own.

Mid Penn Bancorp, Inc. (NASDAQ: MPB), relating to its proposed acquisition of Brunswick Bancorp. Under the terms of the agreement, Brunswick shareholders are expected to receive either 0.598 shares of Mid Penn common stock or $18.00 in cash per share they own.